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Trafficking and expansion of myeloid derived suppressor
cells (MDSCs) plays a major role in immune suppression
of tumor. MDSCs express chemokine receptors which
likely mediate their recruitment to the tumor microenvir-
onment. Suppression of T cells is also mediated by the
interaction of programmed death-1 (PD-1) and its ligands
which are abundantly expressed in cancer cells and
immune infiltrates, including MDSCs. Here, we show that
targeting both pathways through administration of a small
molecule chemokine receptor antagonist (CCX9588 which
blocks CCR1) and an anti-PDL1 antibody significantly
reduced tumor burden in an orthotopic breast cancer
mouse model. Primary tumor growth and lung metastasis
were modestly reduced by either agent (anti-PDL-1 or
CCR1 inhibitor) alone, but the combination of CCR1
inhibitor plus anti-PDL1 antibody resulted in significantly
reduced tumor burden as compared to either of the single
agents. Orthotropic breast cancer cell engraftment induces
robust expansion of CD11b+Ly6Ghi Ly6Chi MDSCs, a
subpopulation of which express CCR1. Analysis of the
tumor infiltrating cells revealed that CCX9588 significantly
reduced the number of MDSCs in primary tumors, sug-
gesting that CCR1 blockade of MDSC trafficking translates
into reduced tumor burden. Finally, analysis of human
breast cancer patient samples from The Cancer Genome
Atlas (TCGA) database revealed that the CCR1 ligands,
CCL3 (MIP-1a) and CCL5 (RANTES) are present at
significantly higher levels in breast cancers as compared to
normal breast tissue. These data are the first to show
that CCR1 chemokine receptor antagonists can act
synergistically with PDL-1 inhibitors, and suggest a novel
approach for potentiating the activity of immune cell
checkpoint inhibitors.
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